Takeda presents updated results for mobocertinib, further substantiating the clinical benefit in patients with egfr exon20 insertion+ mnsclc

Osaka, japan & cambridge, mass.--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced updated data from the phase 1/2 trial of mobocertinib (tak-788) orally administered in patients with epidermal growth factor receptor (egfr) exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mnsclc) who received prior platinum-based chemotherapy. the results showed mobocertinib continued to demonstrate clinically meaningful b
TAK Ratings Summary
TAK Quant Ranking